Spruce biosciences reports full year 2022 financial results and provides corporate updates

South san francisco, calif.--(business wire)---- $sprb--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended december 31, 2022 and provided corporate updates.
SPRB Ratings Summary
SPRB Quant Ranking